Q-omics provides the consensus-scored ZNF516-DT profile across patient tissues and cancer cell-line models. ZNF516-DT expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF516-DT is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, ZNF516-DT RNA expression shows 17,159 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where ZNF516-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF516-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF516-DT survival associations across molecular data types. ZNF516-DT RNA expression shows survival associations in the most cancer types (27). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF516-DT RNA expression–survival associations across cancer types. High ZNF516-DT expression shows unfavorable associations in UVM, LGG and BLCA, but favorable associations in BRCA, OV and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF516-DT RNA expression.
This table summarizes ZNF516-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF516-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF516-DT shows lower tumor expression in KICH and higher tumor expression in BRCA, LIHC, THCA, LUAD and LUSC. The KICH box plot shows higher ZNF516-DT RNA expression in normal versus tumor tissue (log2 FC = −0.285, t-test p < 0.001).
This table shows molecular features associated with ZNF516-DT in patient tissues and cancer cell lines. In patient samples, ZNF516-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
